Similar articles

• Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.

  Lozano-Ortega G, Walker DR, Johnston K, Mickle A, Harrigan S, Rogula B, Kristy RM, Hairston JC, Schermer CR. Lozano-Ortega G, et al. Drugs Aging. 2020 Nov;37(11):801-816. doi: 10.1007/s40266-020-00792-9. Drugs Aging. 2020. PMID: 32960422 Free PMC article.
• Safety and efficacy of an α₁ -blocker plus mirabegron compared with an α₁ -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis.

  Herschorn S, Tarcan T, Jiang YH, Chung E, Abdul Hadi F, Steup A, Sumarsono B. Herschorn S, et al. Neurourol Urodyn. 2024 Mar;43(3):604-619. doi: 10.1002/nau.25399. Epub 2024 Jan 30. Neurourol Urodyn. 2024. PMID: 38291827
• Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.

  Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Wagg A, et al. Curr Med Res Opin. 2016;32(4):621-38. doi: 10.1185/03007995.2016.1149806. Epub 2016 Feb 17. Curr Med Res Opin. 2016. PMID: 26828974
• Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

  Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z. Maman K, et al. Eur Urol. 2014 Apr;65(4):755-65. doi: 10.1016/j.eururo.2013.11.010. Epub 2013 Nov 18. Eur Urol. 2014. PMID: 24275310
• Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?

  Marcelissen TAT, Van Koeveringe GA. Marcelissen TAT, et al. Eur Urol. 2018 Sep;74(3):334-335. doi: 10.1016/j.eururo.2018.04.019. Epub 2018 May 1. Eur Urol. 2018. PMID: 29724504 No abstract available.